Mosaic ImmunoEngineering Inc (CPMV)

[Prudent Capitalist]

Friday's news is difficult to sort out in terms of the prospects for the stock price. But, what is clear is that there have been problems in leadership and execution which would have become even more serious going forward. Better to get things out in the open and deal with it now. Such decisive action could be a positive. Perhaps these problems were known to an extent, and that is what kept the stock from going higher on the news of the 336 recert. We definitely need to get the right executive leadership in place as soon as possible, as there are too many important things going on on multiple strategic fronts. Someone indicated in a post last Friday that this increases the chance of a buyout, but I am not sure. Anyone else have any further thoughts on these issues?